Market cap
$1 Mln
Recently Viewed
Clear All$0.07
$-0.13
(-62.65%)
As on 04-Mar-2024 14:59EDT
Market cap
$1 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
40.3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-22 Mln
ROE
-1.5 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
1.9
Debt to Equity
0
Book Value
$--
EPS
$-1.6
Face value
--
Shares outstanding
9,716,930
CFO
$-497.20 Mln
EBITDA
$-474.57 Mln
Net Profit
$-583.21 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bellicum Pharmaceuticals (BLCM)
| -- | -- | -73.3 | -91.2 | -73.1 | -70.4 | -- |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Bellicum Pharmaceuticals (BLCM)
| -51.7 | -57.8 | -72.6 | -55.8 | -65.1 | -38.3 | -32.8 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's... clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas. Read more
Chief Executive Officer
Mr. David M. Maggio
Chief Executive Officer
Mr. David M. Maggio
Headquarters
Houston, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Bellicum Pharmaceuticals Inc (BLCM) is $0.07 (NASDAQ) as of 04-Mar-2024 14:59 EDT. Bellicum Pharmaceuticals Inc (BLCM) has given a return of -73.13% in the last 3 years.
Since, TTM earnings of Bellicum Pharmaceuticals Inc (BLCM) is negative, P/E ratio is not available.
The P/B ratio of Bellicum Pharmaceuticals Inc (BLCM) is 40.34 times as on 04-Mar-2024, a 815 premium to its peers’ median range of 4.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.17
|
2.06
|
|
2021
|
-2.46
|
0.97
|
|
2020
|
-3.25
|
-11.22
|
|
2019
|
-0.05
|
-0.25
|
|
2018
|
-0.13
|
0.18
|
The 52-week high and low of Bellicum Pharmaceuticals Inc (BLCM) are Rs -- and Rs -- as of 30-Apr-2026.
Bellicum Pharmaceuticals Inc (BLCM) has a market capitalisation of $ 1 Mln as on 04-Mar-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Bellicum Pharmaceuticals Inc (BLCM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.